Xingchen Peng
Overview
Explore the profile of Xingchen Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ren R, Liu J, Li S, Wu X, Peng X, Liao W, et al.
BMC Oral Health
. 2025 Mar;
25(1):328.
PMID: 40025464
Background: The aim of our study was to develop and evaluate a deep learning model (BiStageNet) for automatic detection of dens evaginatus (DE) premolars on orthodontic intraoral photographs. Additionally, based...
2.
Diao J, Wei Z, Pei Y, Ge J, Qing Y, Wei Y, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):129.
PMID: 40024914
Background: Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 inhibitors, have demonstrated significant survival benefits in treating recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). While baseline peripheral blood lymphocyte subsets have been identified...
3.
Gao K, Wei Z, Liu Z, Pei Y, Li H, Song G, et al.
Head Neck
. 2025 Feb;
PMID: 39943747
Background: Neutrophil-to-lymphocyte ratio (NLR) can be treated as a simple indicator of patients' immune status by representing the state of the systemic inflammatory response. Immunotherapy now is the accepted second-line...
4.
Zhang Y, Zhai S, Qin S, Chen Y, Chen K, Huang Z, et al.
Bioeng Transl Med
. 2025 Jan;
10(1):e10709.
PMID: 39801759
The major histocompatibility complex class I (MHCI) trafficking signal (MITD) plays a pivotal role in enhancing the efficacy of mRNA vaccines. However, there was a lack of research investigating its...
5.
Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):72.
PMID: 39751901
Background: Immune checkpoint inhibitors (ICIs) show optimal treatment effects on recurrent or metastatic nasopharyngeal carcinoma(R/M NPC). Nonetheless, whether metastatic sites impact ICIs efficacy remains unclear. Methods: We performed a secondary...
6.
Xu S, He J, Liu Z, Pei Y, Ge J, Qing Y, et al.
Oral Oncol
. 2025 Jan;
161():107161.
PMID: 39746267
Background: Immune-related adverse events (irAEs) have been associated with better therapeutic outcomes in patients receiving immune checkpoint inhibitors (ICIs) across various cancers. This study investigates the association between irAEs and...
7.
Li R, Liu Z, Wei Z, Huang R, Pei Y, Yang J, et al.
J Cancer
. 2025 Jan;
16(2):689-699.
PMID: 39744477
Brain metastases, affecting 30% of solid tumor patients, have a substantial impact on clinical outcomes. Developing a clinically feasible and precise prognostic model is crucial for personalized and comprehensive treatment....
8.
Qi M, Zhou P, Huang S, Su M, Peng X, Huang R
Clin Nucl Med
. 2024 Dec;
50(2):156-164.
PMID: 39668493
Purpose: The aim of this study was to compare the clinical application value of 68 Ga-DOTATATE and 18 F-FDG PET/CT in Epstein-Barr virus (EBV)-positive nonkeratinizing nasopharyngeal carcinoma. Patients And Methods:...
9.
Yang S, Chen R, Wu Y, Song X, Peng X, Chen M
Acta Biomater
. 2024 Dec;
192():340-352.
PMID: 39657865
Latent membrane protein 2 (LMP2), which is an important protein of Epstein-Barr virus (EBV) in the latent phase to mediate metastasis and recurrence, has shown great potential as a targeting...
10.
Song G, Wei Z, Pei Y, Liu Z, Min Y, Li H, et al.
J Inflamm Res
. 2024 Nov;
17:9169-9180.
PMID: 39600680
Purpose: Immunotherapy has become the primary option for recurrent and metastatic nasopharyngeal cancer (R/M NPC) after failure of chemotherapy, but without good prognostic indicators. Our study aimed to assess the...